BR112012026285A2 - combinação de compostos orgânicos - Google Patents
combinação de compostos orgânicosInfo
- Publication number
- BR112012026285A2 BR112012026285A2 BR112012026285A BR112012026285A BR112012026285A2 BR 112012026285 A2 BR112012026285 A2 BR 112012026285A2 BR 112012026285 A BR112012026285 A BR 112012026285A BR 112012026285 A BR112012026285 A BR 112012026285A BR 112012026285 A2 BR112012026285 A2 BR 112012026285A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- organic compounds
- pharmaceutical combination
- benzimidazol
- methylpiperazin
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- 101150097381 Mtor gene Proteins 0.000 abstract 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
combinação de compostos orgânicos. a presente invenção refere-se a uma combinação farmacêutica que compreende 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]-1h-quinolin-2-ona e pelo menos um inibidor de mtor e a combinação farmacêutica para uso no tratamento ou prevenção de uma doença proliferativa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32501810P | 2010-04-16 | 2010-04-16 | |
PCT/EP2011/055908 WO2011128405A1 (en) | 2010-04-16 | 2011-04-14 | Combination of organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012026285A2 true BR112012026285A2 (pt) | 2016-07-12 |
Family
ID=44009923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012026285A BR112012026285A2 (pt) | 2010-04-16 | 2011-04-14 | combinação de compostos orgânicos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20130035343A1 (pt) |
EP (1) | EP2558082A1 (pt) |
JP (1) | JP2013525292A (pt) |
KR (1) | KR20130092412A (pt) |
CN (1) | CN102834094B (pt) |
AU (1) | AU2011240001B2 (pt) |
BR (1) | BR112012026285A2 (pt) |
CA (1) | CA2795089A1 (pt) |
CL (1) | CL2012002858A1 (pt) |
IL (1) | IL222313A0 (pt) |
MA (1) | MA34106B1 (pt) |
MX (1) | MX2012012058A (pt) |
NZ (1) | NZ602807A (pt) |
RU (1) | RU2012148706A (pt) |
SG (1) | SG184311A1 (pt) |
TN (1) | TN2012000477A1 (pt) |
WO (1) | WO2011128405A1 (pt) |
ZA (1) | ZA201207234B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
US20150182525A1 (en) * | 2011-05-19 | 2015-07-02 | Novartis Ag | 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma |
GB201217890D0 (en) * | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
WO2015073691A1 (en) * | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
ATE191218T1 (de) | 1993-12-17 | 2000-04-15 | Novartis Ag | Rapamycin-derivate als immunosuppressoren |
WO1996041807A1 (en) | 1995-06-09 | 1996-12-27 | Novartis Ag | Rapamycin derivatives |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
EP1212331B1 (en) | 1999-08-24 | 2004-04-21 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
PT1650203E (pt) | 2000-09-11 | 2008-05-13 | Novartis Vaccines & Diagnostic | Processo de preparação de derivados de benzimidazol-2-ilquinolinona |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
KR101224410B1 (ko) * | 2003-11-07 | 2013-01-23 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 퀴놀리논 화합물을 합성하는 방법 |
EP1687032B1 (en) * | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc). |
MX2007014206A (es) * | 2005-05-13 | 2008-02-07 | Novartis Ag | Metodos para tratar cancer resistente a los farmacos. |
JP2008542289A (ja) | 2005-05-23 | 2008-11-27 | ノバルティス アクチエンゲゼルシャフト | 4−アミノ−5−フルオロ−3−[6−(4−メチルピペラジン−1イル)−1h−ベンズイミダゾール−2−イル]−1h−キノリン−2−オン乳酸塩の結晶およびその他の形態 |
CA2680161A1 (en) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
-
2011
- 2011-04-14 CA CA2795089A patent/CA2795089A1/en not_active Abandoned
- 2011-04-14 US US13/640,585 patent/US20130035343A1/en not_active Abandoned
- 2011-04-14 RU RU2012148706/15A patent/RU2012148706A/ru not_active Application Discontinuation
- 2011-04-14 EP EP11714304A patent/EP2558082A1/en not_active Withdrawn
- 2011-04-14 MA MA35274A patent/MA34106B1/fr unknown
- 2011-04-14 CN CN201180019352.6A patent/CN102834094B/zh not_active Expired - Fee Related
- 2011-04-14 SG SG2012071924A patent/SG184311A1/en unknown
- 2011-04-14 MX MX2012012058A patent/MX2012012058A/es unknown
- 2011-04-14 WO PCT/EP2011/055908 patent/WO2011128405A1/en active Application Filing
- 2011-04-14 AU AU2011240001A patent/AU2011240001B2/en not_active Ceased
- 2011-04-14 BR BR112012026285A patent/BR112012026285A2/pt not_active IP Right Cessation
- 2011-04-14 NZ NZ602807A patent/NZ602807A/en not_active IP Right Cessation
- 2011-04-14 JP JP2013504277A patent/JP2013525292A/ja active Pending
- 2011-04-14 KR KR1020127029922A patent/KR20130092412A/ko not_active Application Discontinuation
-
2012
- 2012-09-27 ZA ZA2012/07234A patent/ZA201207234B/en unknown
- 2012-10-01 TN TNP2012000477A patent/TN2012000477A1/en unknown
- 2012-10-09 IL IL222313A patent/IL222313A0/en unknown
- 2012-10-12 CL CL2012002858A patent/CL2012002858A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102834094B (zh) | 2015-05-06 |
JP2013525292A (ja) | 2013-06-20 |
RU2012148706A (ru) | 2014-05-27 |
CL2012002858A1 (es) | 2013-01-25 |
MA34106B1 (fr) | 2013-03-05 |
MX2012012058A (es) | 2012-11-22 |
US20130035343A1 (en) | 2013-02-07 |
KR20130092412A (ko) | 2013-08-20 |
IL222313A0 (en) | 2012-12-31 |
AU2011240001A1 (en) | 2012-11-08 |
ZA201207234B (en) | 2013-05-29 |
WO2011128405A1 (en) | 2011-10-20 |
TN2012000477A1 (en) | 2014-04-01 |
CA2795089A1 (en) | 2011-10-20 |
CN102834094A (zh) | 2012-12-19 |
EP2558082A1 (en) | 2013-02-20 |
SG184311A1 (en) | 2012-11-29 |
NZ602807A (en) | 2014-02-28 |
AU2011240001B2 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015006019A2 (pt) | composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção. | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
BR112015008759A2 (pt) | método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
CL2012001752A1 (es) | Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer. | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
CL2013002003A1 (es) | Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
BR112012026285A2 (pt) | combinação de compostos orgânicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |